Decarbonising Pharma webinar: Oligonucleotide Manufacturing
Oligonucleotide-based medicines work by interfering with how genes are expressed and have shown success in the treatment of rare diseases. This next-generation therapeutic class is now being explored to treat chronic diseases that affect much larger patient populations. Their utility, however, is limited by issues within the current manufacturing process. With many prospective oligonucleotide-based medicines already in development and clinical trials, a cost-effective, sustainable and scalable manufacturing method is required to meet current and future manufacturing needs.
At CPI, we are collaborating on several projects with large pharma companies to develop a scalable and sustainable solution phase oligonucleotide manufacturing process. Watch the webinar recording below, hosted by Heather Walton, CPI’s Senior Chemist, to find out more about our future innovation plans surrounding oligonucleotide manufacturing.
This webinar will explore:
- Introduction and application of oligonucleotide therapeutics
- Issues with current manufacturing processes
- Projects with partners, such as AstraZeneca and University of Manchester
- Future of oligonucleotide manufacturing